Most of the studies done in the laboratory under in vitro conditions have hardly-failed when they reach the clinic. And this can easily be explained because tumors do not behave the same on a petri dish (2D) than in a three dimension (3D). Discarding in vivo models, recent approaches have focused on the way to prevent this phenomenon, such as tumor-derived organoids. Despite the fact that this method presents fantastic possibilities, it is still missing some key parameters essential for tumor development and that may be key on how these tumors may response to inhibitors, such as hypoxia, or the impact of stroma between others.

In deed, researchers at Tel-Aviv University have developed a novel 3D-bio-print model of a glioblastoma tumor, one of the deadliest type of brain cancer in order to avoid the the 2D-dependent loss of p-selectin, a protein produced when glioblastoma cancer cells encounter microglia and which is essential to take into account because it forces microglia to support cancer cells instead of attacking them. This 3D bioprint model has been generated with samples from glioblastoma patients obtained from surgery. The most relevants things are probably the fact that it has an intrinsic and functional blood vessel network, which allows the study of drug delivery like if it was a real tumor, but also that it contains the extracellular matrix. You can obtain about 100 small functional tumors from a patient´s sample. Professor Satchi-Fainaro, the main investigator has recently published this amazing work in Science Advances and we are sure that it is going to change the current perspective at the clinic, where they are encountering a devastating 90% failure rate.